| Document |
Document Title |
|
WO/2023/138657A1 |
A quinoline amine compound, a preparation method therefor, and the use thereof in medicine. Specifically, the present disclosure relates to a quinoline amine compound represented by general formula (I), a preparation method therefor, a p...
|
|
WO/2023/138599A1 |
An aromatic fused ring compound which acts as a sodium channel blocker, and a use thereof. The aromatic fused ring compound has inhibitory activity on sodium ion channel Nav1.8, and may be used as a drug for a wide range of pain treatment.
|
|
WO/2023/137548A1 |
The present document describes a livestock dietary supplement composition which comprises a sialagogue comprising cinnamaldehyde, an anti-inflammatory comprising a salicylate, an expectorant comprising menthol, an antimicrobial comprisin...
|
|
WO/2023/138147A1 |
The present invention relates to the field of medicinal chemistry. Disclosed are a triptolide prodrug, a preparation method therefor and a pharmaceutical use thereof. The preparation steps are: 1, making triptolide react with acyl chlori...
|
|
WO/2023/140700A1 |
The present invention provides a composition for treating inflammatory bowel disease or a method for the screening of drugs for treating inflammatory bowel disease, the composition comprising, as an active ingredient, a material for redu...
|
|
WO/2023/140695A1 |
The present invention relates to a composition for improving intestinal health and function comprising: a milk-derived exosomes; and a therapeutic agent, wherein the therapeutic agent is DNA, RNA, or a small molecule, and the therapeutic...
|
|
WO/2023/138317A1 |
Disclosed are a compound having RIPK1 inhibitory activity, a preparation method therefor and the use thereof. The structure of the compound is as shown in general formula I, and the definition of each substituent is as described in the d...
|
|
WO/2023/139233A1 |
The present invention relates to A pharmaceutical combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof, prodrug thereof or a metabolite thereof with a JAK inhibitor or a pharmaceutically acceptable salt ...
|
|
WO/2023/138362A1 |
The present invention relates to a compound of formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a use thereof in the preparation of a drug for treating diseases related to WEE1 activity.
|
|
WO/2023/134472A1 |
A new use of ginsenoside Rd in the preparation of drugs for relieving and/or treating inflammation and health food/medicinal food/functional food/dietary supplements. Ginsenoside Rd is suitable for treating acute inflammation such as inf...
|
|
WO/2023/136470A1 |
The present disclosure relates to a novel PNA monomer and PNA oligomer, in which a primary amine contained in a lysine residue, the N-terminus, or the C-terminus of the PNA oligomer is modified to maintain the positive charge of the PNA ...
|
|
WO/2023/135207A1 |
The present invention relates to a pharmaceutical combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof, prodrug thereof or a metabolite thereof with a S1P receptor modulator or a pharmaceutically accepta...
|
|
WO/2023/134764A1 |
The present invention relates to a pyridine-containing polycyclic derivative, and a preparation method therefor and the use thereof. In particular, the present invention relates to a compound as represented by general formula (I), a prep...
|
|
WO/2023/134137A1 |
The present invention relates to the technical field of bioengineering. Provided in the present disclosure are a composition based on a supramolecular artificial receptor cell, and a preparation method therefor and the use thereof. Provi...
|
|
WO/2023/134713A1 |
The present invention belongs to the field of medicines, and relates to a fused azaheterocyclic compound, a pharmaceutical composition thereof and the use thereof in the preparation of a drug. Specifically, the present invention relates ...
|
|
WO/2023/137353A1 |
Described herein are 15-PGDH inhibitors and methods of utilizing 15-PGDH inhibitors in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
|
|
WO/2023/137166A1 |
Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a me...
|
|
WO/2023/134723A1 |
The present disclosure relates to a crystal form of a neurokinin antagonist prodrug compound. Specifically, the present disclosure relates to a novel crystal form of a compound represented by formula I and a preparation method. The novel...
|
|
WO/2023/137356A1 |
Described herein are 15-PGDH inhibitors and methods of utilizing 15-PGDH inhibitors in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
|
|
WO/2023/135233A1 |
The present invention concerns a compound of formula (I), or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity, in particular ERK2 activity.
|
|
WO/2023/134629A1 |
The present disclosure relates to the field of drugs. Specifically, the present disclosure relates to a compound as represented by formula (I), or a stereoisomer, tautomer, metabolite, pharmaceutically acceptable salt or prodrug of the c...
|
|
WO/2023/135583A1 |
The present invention relates to vitamin nanoclusters (NCs), preferably vitamin D3nanoclusters, having a core-shell structure in which the solid core comprises vitamin, thereby defining a high-density or high-concentrated vitamin core. T...
|
|
WO/2023/135186A1 |
The present invention generally relates to the field of skin care. More particularly, the invention relates to a cosmetic or therapeutic skin care composition comprising live bacteria of at least one Cutibacterium acnes (C. acnes) strain...
|
|
WO/2023/136525A1 |
The purpose of the present invention is to provide a composition for prevention or treatment of particulate matter 2.5 (PM2.5)-induced inflammatory disease, comprising a powdered tea extract as an active ingredient, and more specifically...
|
|
WO/2023/134733A1 |
High penetration prodrugs (HPPs), pharmaceutical compositions and methods thereof, for treatment of signs, symptoms and/or complications of viral, bacterial, protozoal, and/or fungal infections are disclosed. The HPPs are capable of pene...
|
|
WO/2023/134765A1 |
The present invention relates to five-membered-ring-containing derivatives, a preparation method therefor, and the uses thereof. In particular, the present invention relates to compounds represented by a general formula, a preparation me...
|
|
WO/2023/136151A1 |
The present invention addresses the problem of providing a novel ASMT expression promoter and provides an ASMT expression promoter that contains, as an active ingredient, at least one substance selected from the group consisting of eucal...
|
|
WO/2023/134122A1 |
A cell membrane-coated nanodecoy (ND) capable of clearing proinflammatory factors and inhibiting T cell activation, and a preparation method therefor and the use thereof. The nanodecoy comprises: a nano core and a programmed death-ligand...
|
|
WO/2023/135532A1 |
The invention concerns a compound of formula (I) or pharmaceutically acceptable salts or hydrates thereof: (I) wherein R represents a 6-membered aryl or heteroaryl group or a 5-membered heteroaryl group, optionally substituted with at le...
|
|
WO/2023/132681A1 |
The present invention relates to a composition comprising 1-alkyl-5-arylidene-2-selenoxoimidazolidin-4-one and a derivative thereof for prevention, alleviation, or treatment of inflammatory diseases. Specifically, 1-alkyl-5-arylidene-2-s...
|
|
WO/2023/131578A1 |
The present invention relates to a combination of budesonide and 5-amino-2,3-dihydro-1,4- phthalazinedione or one of its pharmaceutically acceptable salts. This pharmaceutical combination shall be used in the treatment of chronic inflamm...
|
|
WO/2023/132399A1 |
The present invention relates to a composition for the prevention, amelioration or treatment of inflammatory bowel disease, comprising a galacto-oligosaccharide as an active ingredient. The galacto-oligosaccharide composition of the pres...
|
|
WO/2023/133319A1 |
Disclosed are methods and related compositions for administering a high affinity IL-2 receptor agonist in combination with immunosuppressants (e.g., comprised in synthetic nanocarriers), wherein the immunosuppressant is at a reduced effe...
|
|
WO/2023/133386A1 |
The present disclosure relates to methods and compositions for oral delivery of nutrients and/or pharmaceuticals, particularly for tissue repair and regeneration of the body, and more particularly to methods and compositions for protecti...
|
|
WO/2023/130205A1 |
The present invention provides a stabilizing solution, a pharmaceutical composition stored or administered in a stabilizing solution form, and a pharmaceutical product of the stabilizing solution and preparation methods and applications ...
|
|
WO/2023/133089A1 |
Provided herein are lipid compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically labeled derivatives, prodrugs, and compositions ther...
|
|
WO/2023/133460A1 |
Disclosed herein are methods of treating an allergic rhinitis, a nasal polyp, and/or a sinusitis in a subject, comprising intranasally administering to the subject a corticosteroid, an ester thereof, or a salt thereof by a nasal spray de...
|
|
WO/2023/131167A1 |
The present invention relates to a compound represented by general formula (I) or a stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or eutectic crystal thereof, an intermediate thereof, a...
|
|
WO/2023/133445A1 |
Disclosed herein are compositions for and methods of treating, preventing, and/or mitigating pain, including both acute and chronic pain, post-surgical pain, cancer pain, injury pain, and pain associated with bone fracture. Disclosed her...
|
|
WO/2023/130160A1 |
The present invention relates to compositions comprising cannabinoids including cannabidiolic acid (CBDA), cannabidiol (CBD), cannabigerol (CBG), cannabidiphorol (CBDP), cannadibutol (CBDB), CBGA (cannabigerolic acid), CBN (cannabinol) a...
|
|
WO/2023/130185A1 |
A transformation vector for stably transforming a plastid is provided. The transformation vector comprises an expression cassette, comprising, as operably-linked components, a regulatory sequence operative in the plastid, a heterologous ...
|
|
WO/2023/130541A1 |
Provided in the present invention are a 2-pyrazole-3-benzimidazole derivative, a preparation method therefor and the use thereof, the 2-pyrazole-3-benzimidazole derivative having a structure represented by formula (I). Experimental resul...
|
|
WO/2023/133476A1 |
Disclosed herein is a method of treating Idiopathic Pulmonary Fibrosis (IPF). The method includes administering to a subject in need thereof the deuterium-enriched pirfenidone LYT-100 at a total daily dose from about 1650 mg to about 250...
|
|
WO/2023/130740A1 |
The present invention belongs to the technical field of biological medicines, and particularly relates to an isaridin cyclic lipopeptide derivative, and a preparation method therefor and the use thereof. Tests prove that the derivative s...
|
|
WO/2023/131142A1 |
A stable solution, a pharmaceutical composition with a storage or administration method as a stable solution, a pharmaceutical product of the stable solution, a preparation method therefor and the use thereof, and a kit. The stable solut...
|
|
WO/2023/130875A1 |
A botulinum toxin protein composition, comprising a botulinum toxin protein and a protein stabilizer. The protein stabilizer is selected from any one of amino acids and amino acid-like compounds, the amino acids being one or more of L-hi...
|
|
WO/2023/130161A1 |
The present invention relates to compositions comprising cannabinoids including cannabidiolic acid (CBDA), cannabidiol (CBD), cannabigerol (CBG), cannabidiphorol (CBDP), cannadibutol (CBDB), CBGA (cannabigerolic acid), CBN (cannabinol), ...
|
|
WO/2023/130354A1 |
Provided are two classes of substances for preventing and/or treating chronic and acute inflammatory disorders. The first study found a new class of TNF inhibitors (PRD, PRD-S, TAD, ZF7 peptide or a mixture thereof) that can be used to t...
|
|
WO/2023/124185A1 |
The invention provides an off-the-shelf human umbilical cord derived mesenchymal stem cell, a preparation method thereof, and an application. The preparation method comprises the following steps: culturing an isolated umbilical cord tiss...
|
|
WO/2023/128987A1 |
The present invention relates to a standardized extract of Allium sativum onions over allicin for use as an anti-inflammatory agent.
|
